Cantex Pharmaceuticals
Clinical trials sponsored by Cantex Pharmaceuticals, explained in plain language.
-
New combo therapy targets deadly brain cancer in early trial
Disease control OngoingThis study tests whether adding the drug azeliragon to standard radiation and chemotherapy is safe for people with newly diagnosed glioblastoma, an aggressive brain cancer. About 18 participants will receive the combination to find the best dose and look for early signs that the …
Phase: PHASE1, PHASE2 • Sponsor: Cantex Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 10:36 UTC
-
New hope for aggressive brain cancer: drug combo shows promise
Disease control OngoingThis study tests a new drug, azeliragon, combined with radiation therapy for people with a specific type of glioblastoma, an aggressive brain cancer. The goal is to see if this combination is safe and can slow cancer growth. About 30 adults with newly diagnosed, unmethylated glio…
Phase: PHASE2 • Sponsor: Cantex Pharmaceuticals • Aim: Disease control
Last updated May 04, 2026 16:19 UTC